In addition, heightened cytokine production from myeloid cells likely contributes to cytokine-release syndrome (CRS) induced by CAR-T cell therapy, and VISTA agonistic may ameliorate the innate inflammation of the CAR-T-induced CRS (53). The gene discussed is VSIR; the disease is congenital rubella syndrome.